

JU
JCWSCS 11 MAR 2004

MAR. 11. 2004 10:27AM

6508454166

JT12 Rec'd PCT/PTO 11 MAR 2004

NO. 8401 P. 1



PCT
Incyte Corporation
Legal Department
3160 Porter Drive
Palo Alto, CA 94304
Telephone: (650) 855-0555
Facsimile: (650) 845-4166
(650) 849-8886

Date: March 11, 2004

To: Office of Initial Patent Examination
Filing Receipt Corrections

Company: USPTO

Fax No.: 703-746-9195

Telephone No.:

From: Lisa McDill

Our Ref. No.: PF-0589 USN

Your Ref. No.: 09/786,133

Page(s): 6 , including cover sheet

Comments:

This facsimile is intended for the addressee only and may contain confidential information. If you have received this facsimile in error, please call us at 650.855.0555 immediately to arrange for its return.

Docket No.: PF-0589 USN

Certificate of Transmission

I hereby certify that this paper is being facsimile transmitted to the attention of Office of Initial Patent Examination, Filing Receipt Corrections, U.S. Patent and Trademark Office to Facsimile No. 703-746-9195 on March 11, 2004.

By: Printed: Lisa McDill

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Au-Young et al.Title: HUMAN MEMBRANE CHANNEL PROTEINSSerial No.: 09/786,133Filing Date: June 11, 2001Examiner: Basi, N.Group Art Unit: 1646

Office of Initial Patent Examination
Filing Receipt Corrections
Fax No.: 703-746-9195

REQUEST FOR A CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt (with red-line markings to note changes) received from the United States Patent and Trademark Office (USPTO) in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

- Under the Section entitled "Domestic Priority data as claimed by applicant", please replace "This application is a 371 of PCT/US99/20468 09/02/1999" with -- This application is a 371 of PCT/US99/20468 09/02/1999 which claims the benefit of 60/155,226 09/02/1998 and claims the benefit of 60/240,932 11/12/1998 and claims the benefit of 60/155,225 12/09/1998 and claims the benefit of 60/155,211 01/26/1999 and claims the benefit of 60/155,263 02/10/1999 --.

Applicants hereby request that the above corrections be entered based on the following enclosed documents:

1. A copy of the 1st page of the Published PCT, application no. PCT/US99/20468 (1 pg.).

119884

1


09/786,133

Docket No.: PF-0589 USN

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

Respectfully submitted,

INCYTE CORPORATION

Date: March 11, 2004

Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

119884

2

09/786,133

Incyte Pharmaceuticals, Inc.
Patent Department
Received

COPY

UNITED STATES
PATENT AND
TRADEMARK OFFICE

NOV 25 2002

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/786,133	08/11/2001	1646	990	PF-0589 USN	16	20	2

CONFIRMATION NO. 5220

Incyte Genomics Inc
3160 Porter Drive
Palo Alto, CA 94304

FILING RECEIPT

OC00000009116784

Date Mailed: 11/19/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Janice Au-Young, Brisbane, CA;
Olga Bandman, Mountain View, CA;
Y. Tom Tang, San Jose, CA;
Roopa Reddy, Sunnyvale, CA;
Jennifer L. Hillman, Mountain View, CA;
Henry Yue, Sunnyvale, CA;
Preeti Lal, Santa Clara, CA;
Neil C. Corley, Castro Valley, CA;
Karl J. Guegler, Menlo Park, CA;
Gina A. Gorgone, Boulder Creek, CA;
Mariah R. Baughn, San Leandro, CA;
Yalda Azimzai, Castro Valley, CA;

Domestic Priority data as claimed by applicant

-- This application is a 371 of PCT/US99/20468 09/02/1999

Foreign Applications *which claims the benefit of 60/185,226 09/02/1998*
and claims the benefit of 60/240,932 11/12/1998
and claims the benefit of 60/185,225 12/09/1998
and claims the benefit of 60/185,211 01/26/1999
and claims the benefit of 60/185,263 02/10/1999 --

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Human membrane channel proteins

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 March 2000 (09.03.2000)

PCT

(10) International Publication Number
WO 00/12711 A3

- (51) International Patent Classification⁷: C12N 15/12, C07K 14/705, 14/47, 16/18, 16/28, C12Q 1/68, A61K 38/17
- (21) International Application Number: PCT/US99/20468
- (22) International Filing Date:
2 September 1999 (02.09.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|---------------|-------------------------------|----|
| 60/155,226 | 2 September 1998 (02.09.1998) | US |
| 09/191,283 | 12 November 1998 (12.11.1998) | US |
| Not furnished | 12 November 1998 (12.11.1998) | US |
| 60/155,225 | 9 December 1998 (09.12.1998) | US |
| 60/155,211 | 26 January 1999 (26.01.1999) | US |
| 60/155,263 | 10 February 1999 (10.02.1999) | US |
- (53) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- | | |
|----------|-------------------------------|
| US | 60/155,226 (CIP) |
| Filed on | 2 September 1998 (02.09.1998) |
| US | 09/191,283 (CIP) |
| Filed on | 12 November 1998 (12.11.1998) |
| US | Not furnished (CIP) |
| Filed on | 12 November 1998 (12.11.1998) |
| US | 60/155,225 (CIP) |
| Filed on | 9 December 1998 (09.12.1998) |
| US | 60/155,211 (CIP) |
| Filed on | 26 January 1999 (26.01.1999) |
| US | 60/155,263 (CIP) |
| Filed on | 10 February 1999 (10.02.1999) |
- (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AU-YOUNG,
- [Continued on next page]

(54) Title: HUMAN MEMBRANE CHANNEL PROTEINS

- 12 VEDPAGSEQVPSAVGSPARETPSOTESPVLDTQDAHQGLGMDPFGMDVFAA 1568324
VPP ++ A P E P P E EQ + +P + AA
- 8 VLQPTGTFQRTGAGPQPEPESKPEANPQEP-EPQPEPEP-EPPEPEPEPEAA GI 2924369
VLQPTGTFQRTGAGPQPEPESKPEANPQEP-EPQPEPEP-EPPEPEPEPEAA
- 72 ESTEYL-KALSSSEDEMEGAQEFESLTPSVLDQASVIAERFVSFSRRSS-VAQE 1568324
+ L ++ E+ EG +QE + PP QAV V +R SS +
- 65 PEVQTLPEPPEVEGDAEAGPSLQEQEADFPQPTSQQA-VKWRPSSWLSW GI 2924369
PEVQTLPEPPEVEGDAEAGPSLQEQEADFPQPTSQQA-VKWRPSSWLSW
- 128 DKSSSGFGSPRIMSRSSSVLSGSENGLARHGSAT 1568324
K P+ V SS +L EG +G+ T
- 122 FAKEMKVVQFVYSSGGQNLAGEGGPDQDGAQT GI 2924369
FAKEMKVVQFVYSSGGQNLAGEGGPDQDGAQT
- 461 PERDCKSPITVPCLOEEAGEPLGCKKRRK-PVLSLFDYEQIMAGE-HSPFKPSSAG 1568324
P+DG PC +G G K PLL ++L ++ PP ES A
- 150 PDQDGAQTLEPQGTGDPGSDGSKISKTKQDEPSLWLLWLEINLEKVLQPFPTSQAW GI 2924369
PDQDGAQTLEPQGTGDPGSDGSKISKTKQDEPSLWLLWLEINLEKVLQPFPTSQAW
- 514 EMSQRFPPNP-PAVSQRTISGGRPSARSPLSPTE 1568324
++ P+ PP + P PS +P PE
- 210 KVEHEGAVLEPDPGTEMEVEPTENPSQPNP-GFVE GI 2924369
KVEHEGAVLEPDPGTEMEVEPTENPSQPNP-GFVE
- 653 EKGPLSPITAGLESSGQGPSSFVALLGQVQFQGSABQPKGEGSRDPADPSQGG 1568324
E+ P P G+ SS P FV L+ + +A QP G +PS G
- 246 EEEPAAEPPQGFQASSLPFGDVRLEWLHLFLEALPQFVHKAABQEPSCFG GI 2924369
EEEPAAEPPQGFQASSLPFGDVRLEWLHLFLEALPQFVHKAABQEPSCFG

(57) Abstract: The invention provides new human membrane channel proteins (MECHP) and polynucleotides which identify and encode MECHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MECHP.

WO 00/12711 A3